store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
RG-12525(NID 525) 是一种可口服且具有选择性和竞争性的白三烯 D (LTD)拮抗剂,对 LTC4,LTD4 和 LTE4 诱导的豚鼠薄壁带收缩有抑制作用,IC50 值分别为 2.6 nM,2.5 nM 和 7 nM。RG-12525 对 CYP3A4 有抑制作用, Ki 值为 0.5 µM。RG-12525 是一种新型高效的 PPAR-γ 激动剂(IC50 值约为 60 nM),具有物种特异性,可用于研究哮喘。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 1,830 | 现货 | ||
5 mg | ¥ 2,890 | 现货 | ||
10 mg | ¥ 4,820 | 现货 | ||
25 mg | ¥ 7,390 | 5日内发货 | ||
50 mg | ¥ 9,960 | 6-8周 | ||
1 mL * 10 mM (in DMSO) | ¥ 3,180 | 现货 |
产品描述 | RG-12525(NID 525) is an orally available, selective and competitive leukotriene D (LTD) antagonist that inhibits LTC4, LTD4 and LTE4-induced contraction of guinea pig thin-walled bands, with IC50 values of 2.6 nM, 2.5 nM, and 7 nM, respectively.RG-12525 inhibits CYP3A4, with a Ki value of 0.5 µM. RG-12525 is a novel and potent PPAR-γ agonist (IC50 value of about 60 nM) with species specificity for the study of asthma. |
靶点活性 | PPARγ:60 nM, LTE4:7 nM (Guinea pig), LTD4:2.5 nM (Guinea pig), 3H-LTD4:3.0nM ( (Ki), LTC4:2.6 nM (Guinea pig), CYP3A4:0.5 μM (Ki) |
体外活性 | RG-12525 competitively inhibits 3H-LTD4 binding to lung membranes (Ki = 3.0 +/- 0.3 nM) and antagonizes the spasmogenic activity of LTC4, LTD4, and LTE4 on lung strips in a competitive manner (KB values = 3 nM), displaying greater than 8000-fold selectivity[1]. RG-12525 (2.5 µM or 25 µM) inhibits the microsomal activity of CYP2C9 and -3A4 but does not significantly inhibit CYP1A2, -2A6, -2C19, or -2D6. Additionally, at 25 µM concentration, RG-12525 causes substantial inhibition at the 5 and 10 µM midazolam concentrations[3]. |
体内活性 | Orally, RG-12525 inhibits LTD4-induced wheal formation with an ED50 of 5 mg/kg and a half-life (t1/2) of 10 hours at 9 mg/kg. It also inhibits LTD4-induced bronchoconstriction with an ED50 of 0.6 mg/kg and anaphylactic death with an ED50 of 2.2 mg/kg and a half-life (t1/2) of 7 hours at 10 mg/kg. Additionally, RG-12525 inhibits antigen-induced bronchoconstriction with an ED50 of 0.6 mg/kg[1]. In the systemic anaphylaxis model, RG-12525 inhibits antigen-induced mortality with an ED50 (95% confidence interval) of 2.2 (0.8-6.4) mg/kg. Furthermore, RG-12525 protects against LTD4-induced bronchoconstriction in a model measuring changes in pulmonary function, with an ED50 of 0.6 (0.4-1.0) mg/kg[2]. |
别名 | NID 525 |
分子量 | 423.47 |
分子式 | C25H21N5O2 |
CAS No. | 120128-20-3 |
store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 10 mg/mL (23.61 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.3614 mL | 11.8072 mL | 23.6144 mL | 59.0361 mL |
5 mM | 0.4723 mL | 2.3614 mL | 4.7229 mL | 11.8072 mL | |
10 mM | 0.2361 mL | 1.1807 mL | 2.3614 mL | 5.9036 mL | |
20 mM | 0.1181 mL | 0.5904 mL | 1.1807 mL | 2.9518 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
RG-12525 120128-20-3 DNA Damage/DNA Repair GPCR/G Protein Metabolism Leukotriene Receptor PPAR RG12525 NID-525 NID 525 NID525 RG 12525 Inhibitor inhibitor inhibit